Compound News and Research

RSS

New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance

A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance.

29 Jul 2024

PUFA metabolites in umbilical cord blood may predict autism spectrum disorder

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects learning capability and social behavior of people.

29 Jul 2024

New zwitterionic polyion developed for effective plasmid DNA delivery in muscle cells

Researchers from Tokyo Metropolitan University have created a new drug delivering molecule, a zwitterionic polymer complex that can help get plasmid DNA inside cells when injected into skeletal muscle, a crucial step in the expression of therapeutic RNA and proteins.

28 Jul 2024

Researchers identify a potential therapeutic target for advanced multiple sclerosis

Researchers from Kyushu University have identified a potential therapeutic target for the treatment of advanced multiple sclerosis (MS), a potentially disabling condition associated with the central nervous system.

25 Jul 2024

Insilico Medicine's PandaOmics Box enhances drug discovery with advanced AI capabilities

The development of innovative medicines is an expensive, time-consuming and risky business. On average, it usually takes at least a decade and billions of dollars to bring a new drug from project initiation to approval.

25 Jul 2024

Breakthrough in acute myeloid leukemia treatment targets stem cells

Acute myeloid leukemia is one of the deadliest cancers. Leukemic stem cells responsible for the disease are highly resistant to treatment.

24 Jul 2024

Kaempferol's promise in fighting triple-negative breast cancer

Review highlights kaempferol's potential in treating triple-negative breast cancer through various anticancer mechanisms and improving chemotherapeutic efficacy.

24 Jul 2024

Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

24 Jul 2024

Saffron: A golden remedy for modern health challenges

Review highlights saffron's potential in preventing and treating various human diseases through its bioactive compounds. Clinical and preclinical studies confirm saffron's benefits in conditions like maculopathy, depression, neurodegenerative diseases, and cancer.

21 Jul 2024

Medical debt doubles risk of skipping mental health care for depression and anxiety

Medical debt is significantly more prevalent among adults with depression or anxiety compared to adults without these mental disorders, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health. Among adults with depression or anxiety, those with medical debt were twice as likely to report having delayed or forgone mental health care in the previous 12 months compared to those without medical debt.

19 Jul 2024

Marine fungus-derived aniquinazolin B could be a potential opioid alternative

Opioids have long been known as natural substances with substantial pharmacological effect. They have been used as effective painkillers.

17 Jul 2024

Novel method enables RNA detection with Cas12 nucleases

CRISPR-Cas systems, defense systems in bacteria, have become a plentiful source of technologies for molecular diagnostics.

17 Jul 2024

Allen Institute launches neuroscience initiatives on perception, recognition, and psychedelics

How do neurons react to magic mushrooms? What happens in the brain when we see motion, or when we recognize grain patterns in a piece of wood? How do our brains track the subtle changes in our friends' appearances over time?

15 Jul 2024

Mitochondrially-targeted antioxidants could reduce SARS-CoV-2 effects across multiple organs

Building upon groundbreaking research demonstrating how the SARS-CoV-2 virus disrupts mitochondrial function in multiple organs, researchers from Children's Hospital of Philadelphia (CHOP) demonstrated that mitochondrially-targeted antioxidants could reduce the effects of the virus while avoiding viral gene mutation resistance, a strategy that may be useful for treating other viruses.

15 Jul 2024

Predicting behavior from image features: Insights from cortical tuning

Researchers investigate whether the human occipital-temporal cortex (OTC) co-represents the semantic and affective content of visual stimuli to guide behavior.

15 Jul 2024

Light-activated drugs: A revolutionary approach in neuropathic pain treatment

Light can be used to activate drugs in specific parts of the body through photopharmacology.

11 Jul 2024

Gut bacteria-metabolized equol shows promise in cancer prevention

Researchers reviewed how soy isoflavones are metabolized by gut bacteria into equol, exploring its role in cancer prevention and treatment. They examined the molecular mechanisms and gut microbiota involved to understand equol's anti-tumor effects.

11 Jul 2024

New consortium receives NIH grant to accelerate development of effective TB treatments

A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).

10 Jul 2024

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Imagine a scenario where a skilled hacker must upload critical software to update a central server and thwart a potentially lethal virus from wreaking havoc across a vast computer network.

10 Jul 2024

Efficient multi-site genome editing with retron-derived multitrons

Genome editing has become a widely adopted technology to modify DNA in cells, allowing scientists to study diseases in the lab and develop therapies that repair disease-causing mutations.

10 Jul 2024

Compound News and Research

New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance

PUFA metabolites in umbilical cord blood may predict autism spectrum disorder

New zwitterionic polyion developed for effective plasmid DNA delivery in muscle cells

Researchers identify a potential therapeutic target for advanced multiple sclerosis

Insilico Medicine's PandaOmics Box enhances drug discovery with advanced AI capabilities

Breakthrough in acute myeloid leukemia treatment targets stem cells

Kaempferol's promise in fighting triple-negative breast cancer

Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

Saffron: A golden remedy for modern health challenges

Medical debt doubles risk of skipping mental health care for depression and anxiety

Marine fungus-derived aniquinazolin B could be a potential opioid alternative

Novel method enables RNA detection with Cas12 nucleases

Allen Institute launches neuroscience initiatives on perception, recognition, and psychedelics

Mitochondrially-targeted antioxidants could reduce SARS-CoV-2 effects across multiple organs

Predicting behavior from image features: Insights from cortical tuning

Light-activated drugs: A revolutionary approach in neuropathic pain treatment

Gut bacteria-metabolized equol shows promise in cancer prevention

New consortium receives NIH grant to accelerate development of effective TB treatments

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Efficient multi-site genome editing with retron-derived multitrons

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News